Adoptive immunotherapy for Cytomegalovirus (CMV) disease in immunocompromised patients

Yonsei Medical Journal

Volumn 45, Issue SUPPL., 2004, Pages 18-22

  Lim, Jong Baeck ^a   Kwon, Oh Hun ^a   Kim, Hyon Suk ^a   Kim, Hyun Ok ^a   Choi, Jong Rak ^a   Provenzano, Maurizio ^b   Stroncek, David ^b  

^a Yonsei University College of Medicine   (South Korea)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CMV pp65; Cytomegalovirus; Cytotoxic T lymphocytes; Immunotherapy

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CALCIUM; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR; VIRUS PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; BONE MARROW SUPPRESSION; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DONOR; FIBROBLAST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCALCEMIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VITRO STUDY; KIDNEY DISEASE; LEUKOPENIA; LYMPHOCYTE CLONE; LYMPHOCYTE TRANSFER; MORBIDITY; MORTALITY; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS REACTIVATION;

EID: 3543028620     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.suppl.18     Document Type: Review

References (45)

1. Stinski MF. Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides. J Virol 1978;26:686-701.
2. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T-lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1991;146:2795-804.
3. Grefte JM, van der Gun BT, Schmolke S, van der Giessen M, van Son WJ, Plachter B, et al. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 1992;73:2923-32.
4. Gilbert MJ, Riddell S, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996;383:720-2.
5. Mocarski ES, Courcelle CT. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott Williams and Wilkins; 2001. p.2629-74.
6. Pass RF. Cytomegalovirus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2001. p.2675-706.
7. Ramsay ME, Miller E, Peckham CS. Outcome of confirmed symptomatic congenital cytomegalovirus infection. Arch Dis Child 1991:66:1068-9.
8. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001;12:848-55.
9. Pouria S, State OI, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. QJM 1998;91:185-9.
10. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J 1999;138:S469-72.
11. AP van den Berg. Cytomegalovirus infection does not increase the risk of vanishing bile duct syndrome after liver transplantation. Transplant Int 1996;9:S171-3.
12. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000;95:2240-5.
13. Ljungman P. Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant 1998;21:S72-4.
14. Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:105-14.
15. Karavellas MP. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700.
16. Zhou YF. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624-30.
17. Carlsson J. Prior cytomegalovirus, Chlamydia pneumoniae or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty. Int J Cardiol 2000;73:165-71.
18. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.
19. Danesh J. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. Am Heart J 1999;138:S434-7.
20. Crumpacker CS. Review article: Drug Therapy: Ganciclovir. N Engl J Med 1996;335:721-9.
21. Curran M, Noble S. Valganciclovir. Drugs 2001;61: 1145-50; discussion 1151-2.
22. Sissons JP, Carmichael AJ. Clinical Aspect and Management of Cytomegalovirus Infection. J Infect 2002;44: 78-83.
23. Zaia JA. Cytomegalovirus Infection. In: Thomas ED, Blume KG, forman SJ, editors. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999. p.560-83.
24. Greenberg PD, Reusser P, Goodrich JM, Riddell SR. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Ann NY Acad Sci 1991;636:184-95.
25. McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-10.
26. Boppana SB, Britt WJ. Recognition of human cytomegalovirus gene products by HCMV- specific cytotoxic T cells. Virology 1996;222:293-6.
27. Diamond DJ, York J, Sun J, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997,90:1751-67.
28. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, et al. The human CTL response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
29. Sun Q, Pollock KE, Burton RL, Dai LJ, Britt W, Emanuel DJ, et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood 1999;94:3242-50.
30. Solache A, Morgan CL, Dodi AI, Morte C, Scott I, Baboonian C, et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus [In Process Citation]. J Immunol 1999;163:5512-8.
31. Alp NJ, Allport TD, Van Zanten J, Rodgers B, Sissons JG, Borysiewicz LK. Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. J Virol 1991;65:4812-20.
32. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 1988;168:919-31.
33. Gilbert MJ, Riddell SR, Li CR, Greenberg PD. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 1993;67:3461-9.
34. McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, et al. Identification fo the major late human cytomegalovirus matrix protein pp65 as target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-10.
35. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70:7569-79.
36. Provenzano M, Lim JB, Mocellin S, Monsurro V, Bettinotti M, Marincola FM, et al. The matrix protein pp65 (341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele. Transfusion 2003 Nov;43:1567-74.
37. Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computor algorithm and an enzyme-linked immunospot assay. Blood 2001:98;1872-81.
38. Wills MR, Carmichael AJ, Weekes MP, Mynard K, Okecha G, Sissons JGP. Human virus-specific CD8+ CTL clones revert from CD45R0high to CD45RAhigh in vivo: CD45RA high CD8+ T cells comprise both naive cells and memory cells. J Immunol 1999;162:7080-7.
39. Reddehase MJ, Weiland F, Munch K, Jonjic S, Luske A, Koszinowski UH. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 1985;55:264-73.
40. Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 1987;61:3102-8.
41. Steffens HP, Kurz S, Holtappels R, Reddehase MJ. Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of laten viral genomes, and reduces the risk of virus recurrence. J Virol 1998; 72:1797-804.
42. Podlech J, Holtappels R, Wirtz N, Steffens HP, Reddehase MJ. Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J Gen Virol 1998;79:2099-104.
43. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992;257:238-41.
44. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;334: 601.
45. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99: 3916-22.